Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2919)	5/23/1999 10:18:00 PM
From: Biomaven	Respond to of 10280

BJ: According to SEPR, it is only one isomer of one active metabolite (+ desmethylsibutramine) that is free of the hypertension and anticholinergic side effects of the parent. Here is a link (I also posted this previously on another thread) to the pharmacology of sibutramine: rxlist.com At the annual meeting, they were not focused on +desmethylsibutramine as a weight loss drug at all. I don't know if this is a pharmacological issue (it doesn't work for weight loss); a patent issue (Knoll has a bunch of use patents floating around in addition to its composition of matter patent) or a partnering issue. (From one of their slides from a few months back, the possible indications shown for their ICE were stress incontinence, fecal incontinence, chronic pain, depression, anxiety, ADD and obesity.) At this point you are probably right to maintain a skeptical attitude, though. As this hasn't entered the clinic yet, I can't see how they can be certain of the absence of hypertensive side effects in humans yet. Peter